Pancreatic cancer is one of the most aggressive and devastating human malignancies. There is an urgent need for more effective therapy for patients with advanced disease. In this context, genetic therapy potentially represents a rational new approach to treating pancreatic cancer, which could provide an adjunct to conventional options. Because of the promise of recombinant SV40 vectors, we tested their ability to deliver a transgene, and to target a transcript, so as to inhibit pancreatic tumors growth in vivo. BxPC3 and Capan-1 cells were efficiently transduced using SV40 vectors without selection, as compared to synthetic vectors PEI. SV40 vectors were as efficient as adenoviral vectors, and provided long-term transgene expression. Next, we devised a SV40-derived, targeted gene therapy approach of pancreatic cancer, by combining hTR tumor-specific promoter with sst2 somatostatin receptor tumor-suppressor gene. In vitro cell proliferation was strongly impaired following administration of SV(hTR-sst2). SV40-derived sst2-mediated antiproliferative effect was dependent on the local production of somatostatin. In vivo, intratumoral gene transfer of sst2 using rSV40 vectors resulted in a marked inhibition of Capan-1 tumor progression, and proliferation. These results represent the initial steps toward a novel approach to the gene therapy of pancreatic cancer using SV40 as a vector.
Introduction
Pancreatic cancer is a serious health problem largely because of its poor outcome. 1 Less than 1% of patients will survive 5 years. 2, 3 The reasons for such a poor prognosis include: (1) the difficulty of early diagnosis due to its anatomical location and lack of specific early symptoms, (2) its tendency to spread to surrounding vital organs and to seed the peritoneal cavity, (3) the poor response to existing chemo-, radio-, endocrine or immune therapy. 4 Since the middle of the 1990s, gemcitabine, a nucleoside analog of cytidine, has been the standard firstline therapy for patients with advanced pancreatic cancer. 5 Unfortunately, the median survival time for these patients continues to be less than 6-8 months. 6, 7 In addition, recently published in vitro data have shown that prolonged exposure to gemcitabine led to acquired resistance in some pancreatic cancer cells. 8 Therefore, new strategies are needed to improve overall survival, decrease treatment-associated morbidity and facilitate standard procedures such as tumor resection. In this context, gene therapy represents a different type of approach to treating pancreatic cancer, one which could provide an adjunct to conventional modalities. Viral-mediated gene delivery is currently the most efficient gene transfer method, and of these viral vectors, recombinant adenovirus (AdV) is probably the most efficient. AdV can transduce a variety of normal and tumor-derived cell types, including the liver, skeletal muscle, heart, brain and lung. However, adenoviral vectors do elicit a potent immune response [9] [10] [11] and induce pancreatitis 10 when injected in vivo. In addition, some cancer cell lines, including pancreatic cancer-derived cell lines, are quite refractory to adenoviral infection due to a deficit in b3-integrin and Coxsackievirus Adenovirus Receptor (CAR) expression. 12 Thus, safe and efficient therapeutic gene delivery to pancreatic cells continues to present challenges.
Recombinant, T-antigen (tag) deleted, SV40 is a double-stranded DNA vector that does not elicit significant inflammatory or immune responses, making it a particularly promising gene delivery vector. 13 SV40-derived, tag deleted vectors are replication incompetent and deliver stable transgene expression with high efficiency to unselected cells of many different lineages, in vitro and in vivo. 13 These vectors can be easily prepared without helper viruses, and concentrated to high titer following purification (10 12 infectious units/ml). 13 We thus tested whether SV40 vectors could transduce human pancreatic cancer cells, maintain transgene expression without selection throughout in vitro cell culture, and slow pancreatic tumor progression in vivo.
Material and methods

Reagents and materials
Dulbecco's modified Eagle's medium (DMEM), Rosewell's Park Memorial Institute media (RPMI)-1640, fungizone, penicillin, streptomycin, trypsin and fetal calf serum (FCS) were purchased from Invitrogen (Cergy Pontoise, France). The antimycoplasma agent, Plasmocin was provided by InvivoGen (Toulouse, France). ExGen 500/PEI in vivo was from Euromedex (Souffelheim, France). RNAble was from Eurobio (Les Ulis, France). RNAsin was from Promega (Charbonnie`res, France). Oligonucleotides, SuperScript II reverse transcriptase, Taq polymerase and Rnase-free DNase I were from Invitrogen (Cergy Pontoise, France).
Cell lines
Capan-1 and BxPC3 human pancreatic carcinoma cells (derived from human liver metastasis of pancreatic origin and primary pancreatic adenocarcinoma, respectively) were cultured in RPMI-1640 (Capan-1) or DMEM (BxPC3) medium supplemented with 10% fetal calf serum (FCS) (complete medium). We previously demonstrated that both cell lines do not expressed sst2 receptor.
14,15 293 and COS-7 cells were from American Type Culture Collection (ATCC, Bethesda, MD, USA) and cultured in DMEM supplemented with 5% FCS. All cells were maintained in culture medium supplemented with fungizone, antibiotics, L-Glutamine and antimycoplasma reagent (Plasmocint, InvivoGen) and kept at 371C and 5% CO2.
Plasmid constructions
Primers carrying XhoI and KpnI restriction sites were used for polymerase chain reaction (PCR) with human telomerase reverse transcriptase (hTERT) and hTR promoters as template to generate a series of fragments with compatible ends for cloning in pGL3-basic plasmid (Promega France, Charbonnie`res, France). hTERT 16 and hTR 17 promoters were amplified from normal human lymphocyte genomic DNA using expand PCR cloning kit (Roche Diagnostics, Meylan, France) and primer pairs 5 0 -gggtacccgtccggcattcgt-3 0 , 5 0 -gcagcgctgcctgccgctcgagcgg-3 0 , 5 0 -ccactgagccgagacaag-3 0 and 5 0 -tacgccttctctgttagg-3 0 , respectively. To make pGL3-hTR(sst2), a FLAG-tagged human somatostatin receptor sst2 was cloned as a XhoIXbaI fragment into pGL3-hTR instead of firefly Luciferase cDNA. All resulting plasmids were verified by DNA sequencing (Applied Biosystems, Foster City, CA USA).
Production of recombinant Adv(GFP)
A recombinant E1 deleted serotype 5 Ad expressing GFP (AdvGFP) was constructed and produced as previously described. 18 Adenoviral vectors were purified through two cesium chloride gradients and titrated by end point dilution as described previously. 19 All vector preparations were certified E1-free by PCR. For transduction, Capan-1 cells were seeded into 25 cm 2 -flasks at a density of 0.2 Â 10 6 cells per flask in complete medium. After 48 h, cells were infected with 50 multiplicity of infection (MOI) of Adv(GFP) in RPMI medium supplemented with 2% FCS. After 4 h, medium was changed for complete medium.
Transient transfection using PEI When performing fluorescence-activated cell sorting (FACS) analysis for transfection efficiency studies, Capan-1 and BxPC3 cells were seeded in 75 cm 2 -flasks at a density of 1 Â 10 6 cells per flask in complete medium. After 48 h, cells were transfected with 5 mg of plasmid DNA, using nine equivalents of PEI in absence of serum for 5 h. Transfection medium was changed, and cells were cultured for 2 days in complete medium.
For luciferase activity, 10 5 Capan-1 or BxPC3 cells seeded in a 35-mm tissue culture dish were exposed to transfection mixtures containing 1.5 mg of luciferase reporter plasmids and 0.5 mg of pSV-b-galactosidase control vector (Promega) for 3 h at 371C. Cells were harvested 48 h later, and luciferase assay was performed according to the manufacturer's protocols (Promega). Galactosidase assay was performed concomitantly to standardize for transfection efficiency. As a control, promoter-free plasmid was used (pGL3 basic, Promega). All experiments were performed at least three times and represent the averaged relative luciferase activity.
Production of recombinant SV40 plasmids
We used four different rSV40 vectors, constructed as described 20 from cloned SV40 genomes from which the tag gene was deleted. pSBu(Luc) carries the Firefly luciferase cDNA, which expression is driven by SV40 immediate early promoter. 21 pT7A5(RFP) carries a cDNA encoding red fluorescent protein' which expression is driven by the cytomegalovirus (CMV) promoter. 22 To make pT7(hTR-sst2), pT7A5 was digested using Bstx1 and SpeI restriction enzymes (Euromedex, Mundolsheim, France) to remove the CMV promoter. The resulting plasmid pT7A5DCMV was then blunted using DNA polymerase I Large (AQ2Klenow) fragment (Promega France, Charbonnie`res, France). The hTR-sst2 expression cassette was amplified by PCR from pGL3(hTR-sst2) using primer pair 5 0 -atggacatggcggatgagcc-3 0 and 5 0 -gctcagatactggtttggag-3 0 . After dephosphoylation of pT7A5DCMV using calf instestine alcaline phosphatase (Euromedex, Mundolsheim, France), hTR-sst2 cassette was cloned as a blunted PCR fragment into pT7A5DCMV to give pT7A5(hTR-sst2), and further SV(hTR-sst2) SV40-derived viral vector. SV(A5), originating from pT7A5DCMV, was used as a control, nonexpressing, SV40 recombinant vector for these studies. All plasmids were confirmed by sequencing (Applied Biosystems, Foster City, CA USA). The general principles for making recombinant, replication-defective SV40 viral vectors have been already reported elsewhere. 23 ,24 SV40 stocks were titered by real-time quantitative Q-PCR as previously described, 25, 26 with some modifications. Recombinant viral DNA was purified as previously described. 27 Titration of rSV40 particles was performed by quantitative PCR (Q-PCR) using SYBR GREEN PCR master mix (Applied Biosystems, Foster City, CA, USA). Three different pairs of primers were used. To amplify the SV40 ORI, we used SV40IEP1S (5 0 -gcc tct tga cta ctt ctg gaa tag ct-3 0 ) and SV40IEP1AS (5 0 -ccc agt tcc gcc cat tct-3 0 ). For amplification of the luciferase transgene, we used primers LUC1F (5 0 -ggc gcg tta ttt atc gga gtt-3 0 ) and LUC1R (5 0 -ttc ata ctg ttg agc aat tca cgt t-3 0 ). To amplify the sst2 transgene, we used primers SST2sense (5 0 -ttt tgt ggt ctg cat cat tgg-3 0 ) and SST2AS (5 0 -aaa ggc aga ccc agc atg aa-3 0 ). The Q-PCR was performed with 10-fold serial dilutions of the SV40 and transgene-carrying sequence plasmid as standards, 5 ml of distilled water as a negative control, and 5 ml of each viral DNA diluted 1/50 and 1/100. PCR was performed following the manufacturer's instructions (Gene Amp 5700; Applied Biosystems, Foster City, CA, USA). The following conditions were used: 951C for 10 min and 40 cycles at 951C for 10 s, 501C for 1 min and 601C for 20 s. We routinely obtained 10 9 -10 10 infectious units (IU)/ml. All vector preparations were certified Tagfree by PCR. For transduction, we treated BxPC3 and Capan-1 human pancreatic adenocacinoma-derived cells with recombinant SV40 viral vectors, with a single exposure for 24 h at MOI of 200. 24 All of these studies used unselected cell populations.
Preparation of paraffin-embedded sections
Tumors were harvested and fixed in formalin. Fourmicrometer-thick sections were prepared from paraffinembedded sections. Sections were deparaffinized in xylene, and rehydrated in descending grades (100-50%) of ethanol with a final wash in phosphate-buffered saline (PBS). Sections were incubated in 10 mM citrate buffer (pH 6.0), and microwave irradiated for three 5-min cycles, using a microwave oven operating at 750 W, for antigen retrieval. After three washes in PBS (pH 7.4), sections were incubated for 10 min in a Protein Block, Serum-free reagent (Dako Corp.) to reduce background staining.
Immunostaining for protein expression
To detect human sst2 receptor, slides were incubated for 3 h with rabbit anti-sst2 (1:500), or Mib1 (Ki67, Dako, Glostrup, Denmark) monoclonal antibody (1:100), followed by Cy3-goat-anti-rabbit IgG (1:300) for 1 h. Antibody incubations were performed in PBS supplemented with 1% gelatine at room temperature. Resulting immunostaining was detected with an optical microscope, and quantified on 15 fields using VisioLab2000 image analyzer (Biocom, France).
Western blotting analysis
Total cellular proteins were solubilized in lysis buffer (50 mM 2-[4-(2-hydroxyethyl)-1-piperazinyl]ethanesulfonic acid, 150 mM NaCl, 10 mM ethylenediamine-N,N,N 0 ,N 0 -tetraacetic acid, 10 mM Na 4 P 2 O 7 , 100 mM NaF, 2 mM sodium orthovanadate -pH 7.4) containing 0.1% NP40, 0.01% soybean trypsin inhibitor and 1 mM phenylmethylsulfonylfluoride in the presence of 20 mg/ml aprotinin and 20 mM leupeptin. The mixture was gently agitated for 20 min at 41C and centrifuged at 12 000 g for 10 min to remove cell debris. For immunoblotting, 50 mg of soluble proteins were resolved through 4-20% sodium dodecyl sulfate-polyacrylamide gradient gels, and transferred to a nitrocellulose membrane. After room temperature blocking for 1 h in PBS (pH 7.4)/0.1% Tween-20 containing 5% milk, blots were incubated with either mouse monoclonal anti-FLAG antibody (1:250, SigmaAldrich, Lyon, France), or antiglyceraldehyde-3-phosphate dehydrogenase (GAPDH) antibody (1:1000, Santa Cruz Biotechnology, Sc-38) as a control in PBS (pH 7.4)/ 0.1% Tween-20 containing 1% milk overnight at 41C. Secondary antibodies of goat anti-mouse horseradish peroxidase-conjugated antibodies (1:10 000, Perbio Science, Belgium) were added, and blots were incubated for 1 h at room temperature. Each antibody incubations was followed by four washes in PBS (pH 7.4)/0.1% Tween-20. Immunoreactive proteins were visualized by the ECL immunodetection system.
PCR analyses
PCR analyses of total DNA from transduced cells used primers specific for a portion of the SV(hTR-sst2) genome, located in the 5 0 end of the hTR promoter gene and extending beyond the SV40 late polyadenylation signal. We applied standard PCR techniques, 28 using b-actin detection as a control.
Flow cytometry
Cells were transduced with either AdV(GFP), SV(RFP), or respective controls as described before. Fluorescence was detected 48-96 h later using Becton-Dickinson FACScalibur flow cytometer (Mountain View, CA, USA).
Cell growth assay
Capan-1 cells transduced with SV(hTR-sst2), SV(A5) or left untransduced (mock) were cultured in complete RPMI medium and plated in 35-mm dishes at 50 Â 10 3 cells per ml (2 ml per dish). 24 and 48 h later, cell growth was measured by cell counting using a Coulter counter model ZM as previously described. 29 In vivo gene transfer The animals were acclimatized in a temperature-controlled room under a 12-h light/12-h dark schedule and received pelleted diet and water. Tumor implantation in nude mice. Exponentially growing Capan-1 cells (10 7 ) were inoculated subcutaneously (s.c.) into 8-week-old athymic female nude mice (Swiss nude/nude; IFFA-CREDO, l 0 Abresle, France) that were bred and maintained in pathogen-free conditions. Capan-1 cells were injected s.c. in 0.5 ml of FCS-free RPMI 1640 medium (5 mice/group) by means of sterile 27G catheter set (Vygon, Ecouen, France). Xenografts grew rapidly and were palpable 11-14 days postimplantation. S.c. tumors was determined using vernier calipers according to
, where L ¼ length (mm) and W ¼ width (mm), using width as the smaller dimension. On day 14-17 after xenograft, intratumoral in vivo gene transfer of B2.5 Â 10 10 copies of either SV(A5) and SV(hTR-sst2) vectors was performed using a sterile 29G lymphography catheter set with a sterile, 29G insulin needle. Tumor size was monitored up to 26 days following gene transfer. Each experimental group comprised five animals. Two sets of gene transfer experiments were conducted. Experiments were performed according to the rules of animal ethical committee. At the time of the experiment completion, mice were killed, tumors were sampled and fixed in formalin for further immunohistochemical studies.
Determination of gene expression using real timepolymerase chain reaction Capan-1 cells were transduced with either SV(hTR-sst2) or SV(A5) as described in Material and methods. After 2 weeks, SV40-transduced cells were homogenized in RNAble and total RNA was extracted by the modified procedure of Chomczynski and Sacchi. 30 Before reverse transcription, 1 mg of total RNA was subjected to an RNAse-free DNAse I treatment to eliminate genomic DNA. Real time-polymerase chain reaction (RT-PCR) was performed using specific sense and antisense primers for human sst2 receptor and somatostatin mRNA as previously described. 15, 31 Statistical analysis Results are expressed as mean7standard error (s.e.). Student's t-test was used to compare data (*Po0.05, **Po0.01). Po0.05 was considered significant.
Results
Transduction of pancreatic cancer cells with SV40 vectors
To compare the transduction efficiencies of adenoviral and SV40 vectors in pancreatic cancer cells, we delivered AdV(GFP) and SV(RFP) to Capan-1 cells, in vitro. As a control, we used polyethylenimine (PEI) cationic derivatives, proved to be efficient for gene transfer in vitro and in vivo, particularly in pancreatic cancer cells. 32 Significant GFP expression was detected by FACS analysis and fluorescence microscopy in Capan-1 cells 48 h posttransduction with 50 MOI AdV(GFP) (50.376.5%). However, Capan-1 and BxPC3 cells were scarcely transfected using PEI (Figure 1a and b) . Using adenoviral vectors at higher MOI caused Capan-1 cell death, in vitro (data not shown).
We next assayed the ability of SV40 vectors to transduce pancreatic cancer cells. Thus, Capan-1 cells were treated as described in Material and methods with a recombinant SV40 vector encoding for red fluorescent protein (SV(RFP)). As a control, cells were transduced with a transgene-free SV40 vector (SV(A5)). Using FACS analysis and fluorescence microscopy, we found that Capan-1 cell population was strongly positive for dsRED, Long-term transgene expression in pancreatic cancer cells using SV40 vectors To address the longevity of transgene expression in pancreatic cancer cells using SV40 vectors, Capan-1 and BxPC3 cells were transduced as described in Material and methods with 200 MOI of SV(Luc), encoding for firefly luciferase. Control cells were mock-transduced with SV(A5), or transfected with PEI:Luc complex. Efficient luciferase delivery using rSV40 was verified by immunostaining (data not shown). Cells were passaged every 3-4 days and cultured up to 30 days following gene transfer. As expected, PEI:Luc complex generated detectable levels of luciferase activity following transfection of both Capan-1 and BxPC3 cells (Figure 2a and b) . However, luciferase activity waned as expected 7-12 days following transfection. On the other hand, transduction with SV(Luc) vectors elicited high levels of luciferase activity in both pancreatic cell lines tested compared to PEI transfection (Figure 2a and b) . SV40-driven luciferase activity decreased 10 days following gene transfer, but was stable for the duration of the experiment, that is, up to 30 days following gene transfer.
Expression of somatostatin receptor sst2 in pancreatic cancer cell lines following recombinant SV40 vectors administration We recently proposed human somatostatin receptor sst2 as a potential tumor-suppressor gene for pancreatic cancer. Clinically, sst2 gene expression is inactivated in 90% of pancreatic tumors and pancreatic cancer-derived cell lines. 15 We established that in vitro cell growth and in vivo tumorigenicity were strongly impaired in pancreatic cancer-derived cells genetically modified to express sst2, this effect being dependant on the local production of somatostatin by the transfected cells. 14, 33, 34 We also demonstrated that in vivo sst2 gene delivery using linear synthetic polymers of PEI could transiently inhibit pancreatic tumor progression. 32, 33 As suboptimal delivery characteristics offered by PEI synthetic vector might be limiting, we thought that use of emerging new gene transfer modality, such as SV40 vectors, may reveal whether sustained expression of sst2 leads to a more impressive therapeutic efficacy. In support of the above considerations, we designed a recombinant SV40 vector to deliver sst2 receptor into pancreatic cancer cells.
Telomerase is essentially inactive in most differentiated or committed somatic cells, whereas cancer cells needed to maintain telomerase activity to achieve perpetual proliferation. 35 The human telomerase core enzyme consists of an essential RNA molecule, hTR, with a template domain for telomeric DNA synthesis and of a catalytic protein, hTERT, with reverse transcriptase activity. Aberrant telomerase expression has been extensively used to design gene therapy approaches in which promoters of both telomerase subunits would be used to direct the expression of a therapeutic transgene, in vitro and in vivo.
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Thus, hTERT and hTR promoters appear to be excellent candidates for generating cancer-specific SV40 vectors.
We measured the level of gene expression driven by the telomerase promoters in pancreatic cancer cells using luciferase reporter plasmids following transient transfection. Cells were cotransfected with a b-Gal-encoding plasmid as a transcriptional control. We found that the transcriptional activity of the hTR promoter was consistently stronger than that of the hTERT promoter (Figure 3a) . For comparison purposes, hTR promoter activity was 3-10 times higher than that of hTERT promoter, and equivalent to 0.1-1% of CMV promoter activity. These findings suggest that hTR transcription is significantly activated and that hTR promoter is suitable to drive transgene expression in pancreatic cancer cells. Consequently, we designed a recombinant SV40 vector in which sst2 gene expression was driven by the hTR promoter (SV(hTR-sst2), Figure 3b ). To assess the ability of this SV40 vector to drive detectable expression of somatostatin receptor sst2 in sst2-negative pancreatic cancer cells, Capan-1 cells were transduced as described in Material and methods with 200 MOI of SV(hTR-sst2). Control cells were transduced with SV(A5). At 4 days after transduction, SV(hTR-sst2) viral vector genome was readily detected in the cultured pancreatic cancer cells (Figure 4a) . Next, expression of sst2 was assayed by immunostaining, 2-4 weeks following transduction. SV40-delivered transgene expression was detected in 480% of unselected Capan-1 pancreatic cancer cells (Figure 4b ). Successful sst2 expression in SV(hTR-sst2)-transduced cells was latter confirmed by Western blotting (Figure 4c ). Taken together, these results demonstrated that SV(hTR-sst2) vectors conferred detectable long-term sst2 expression without selection to pancreatic cancer-derived Capan-1 cells. Figure 3 hTR promoter drives detectable transgene expression in pancreatic cancer cells. (a) Capan-1 and BxPC3 cells were transfected with hTR or hTERT-driven luciferase cDNA containing plasmids using PEI as described in Material and methods. As a control, cells were transfected with pGL3-basic promoter-free plasmid. After 48 h, luciferase activity was determined as described in Material and methods. Results are means þ s.e. of five experiments performed in triplicate. (b) Genomic map of SV(hTRsst2) viral vector. In the pT7(hTR-sst2) construct, the hTR promoter drives expression of a C-term FLAG-tagged sst2 cDNA. The promoter drives expression anticlockwise. Remaining wtSV40 sequences in this construct include the three major structural proteins, VP1, VP2 and VP3, and the SV40 ori, enhancer, and encapsidation sequences. The ori overlaps the SV40 early promoter (SV40-EP). Thus, the latter cannot be excised. Transcription driven by SV40-EP is blocked by two tandem polyadenylation signals (pA). The viral genome lacks the early genes, Tag and tag. A carrier plasmid, modified from pT7Blue is used. Inhibition of Capan-1 cells proliferation in vitro and in vivo following SV(hTR-sst2) vector administration We next assayed whether SV40-delivered sst2 receptor might inhibit pancreatic cancer cell proliferation. Thus, Capan-1 cells were transduced as described in Materials and Methods with 200 MOI of SV(hTR-sst2) and SV(A5), or mock-transduced. At 2 weeks after transduction, cell proliferation was assayed on unselected Capan-1 cells. As shown in Figure 5a , SV(hTR-sst2)-transduced Capan-1 cells showed a significant reduction of in vitro cell proliferation as compared with control cells (À9276%). By RT-PCR analysis, we next demonstrated that SV40-derived sst2 expression in Capan-1 cells induced somatostatin production, as compared with control cells (Figure 5a, Inset) .
We then tested whether SV40-driven expression of sst2 receptor could inhibit growth of pancreatic cancer, in vivo. As observed in Figure 5b , SV(A5)-injected, sst2-negative, Capan-1 tumors grew rapidly ( þ 10217105%) by 26 days following gene transfer. In contrast, growth of sst2-transferred Capan-1 tumors was strongly inhibited (À47.575%, compared to control). Interestingly, SV(hTR-sst2)-transferred Capan-1 tumors did not progressed between 17 and 26 days following gene administration. By immunofluorescence, we demonstrated that 5675% of the Capan-1 tumor cells were positive for sst2 at the time of the experiment completion (Figure 5c ). In addition, detection of proliferating cell nuclear antigen Ki67 by immunocheministry demonstrated a significant decrease in the number of tumor cells in cell cycle, in sst2-transferred tumors when compared with control tumors (À56.573.6%; Figure 5d and e). Taken together, these data demonstrate efficient gene delivery in vitro and in vivo in pancreatic cancer-derived cells using recombinant SV40 vectors. Furthermore, expressing somatostatin sst2 receptor in pancreatic cancer cells using recombinant SV40 vectors strongly antagonized in vitro cell proliferation, and in vivo tumor growth.
Discussion
The dismal prognosis associated with pancreatic cancer is a consequence of difficulties in early detection combined with a lack in effective therapeutic options. Despite several phase II trials of chemotherapy regimens, no clinically meaningful gains have yet been recorded for the treatment of pancreatic cancer. Thus, there is an urgent need for more effective therapy for patients with advanced disease. In this context, gene therapy represents a rational new approach to pancreatic cancer treatment, one which could provide an adjunct to conventional options. Many different gene-transfer systems are being developed for numerous applications. Each of the envisaged applications has is own particular requirements and therefore a generally applicable ideal vector is not likely to exist. We and others have recently turned to gene therapy using diverse suicide genes, cytokines, proapoptotic or antiangiogenic moieties via liposome-mediated gene transfer, 32, [41] [42] [43] or by using retroviral, adenoassociated or adenoviral vectors that were consequently used to transduce cancer cells in vitro and in vivo, 32, [44] [45] [46] [47] [48] Although these studies offer new alternatives and are potentially promising, they nevertheless face many of the obstacles that are inherent to their respective systems.
The transduction rate for nonviral vectors, despite multiple and prolonged exposures, remains low. Some studies do demonstrate success, but lacked cell-type specificity and low transduction efficacy remain problematic. For viral vectors, recombinant retroviral delivery is limited in part by their ability to induce insertional mutagenesis. AdV-based vectors have the added complication of eliciting strong immune responses in the host, possibly preventing further in vivo applications. In mice, AdV has been shown to transduce pancreatic cells efficiently in vivo, but expression of the transgene is transient, and the viral proteins elicit a potent immune response. 9, 10, 49 In addition, administration of AdV to the mouse pancreas results in significantly decreased intracellular amylase levels and associated histologic damage, suggesting that the vector is quite toxic to the organ. 10 The advantages of adeno-associated viral vectors include a lack of pathogenicity, less immunogenicity and stable expression. 50, 51 However, several weeks are necessary to reach therapeutic level of transgene expression. Indeed, to be effective in transplanted animal cancer models, AAV vectors have had to be injected before tumor inoculation, which is clinically irrelevant. 47 In such a context, replication-deficient SV40-based vectors may offer an attractive alternative. SV40 infects a wide range of cell types from humans and other mammals, ensuring that recombinant SV40 vectors can deliver transgenes to almost any type of mammalian cell. [52] [53] [54] [55] [56] [57] [58] In this study, we tested the ability of recombinant SV40 vectors to modify pancreatic tumor as targets for cancer gene therapy. We demonstrated that SV40 vectors transduced human pancreatic cancer-derived cells with high efficacy and without detectable toxicity. FACS and immunofluorescence studies demonstrated that at least two-third of the cell population was efficiently transduced after a single inoculation of reporter SV40 vectors, without selection. For comparison, we demonstrated that SV40 vectors were as efficient as adenoviral vectors in transducing pancreatic cancer cells. On the other hand, PEI complex scarcely transfected both Capan-1 and BxPC3 cells, confirming previous reports. 32, 33, 59 Previous work suggested that recombinant SV40 gene delivery could result in long-term transgene expression. For example, transplanting rSV40-transduced bone marrow cells into irradiated compatible recipients resulted in continuous transgene expression in large percentages of bone marrow and peripheral blood cells in both rodents 53, 57, 60 and nonhuman primates (unpublished data) for many months following transplantation. The durability of transgene expression has not been limited to cycling cells; transduction of the liver led to stable and permanent correction of a metabolic abnormality 61 and provided long-lasting serum levels of transgene products. 62 To evaluate the durability of transgene expression in continuously dividing cells, we transduced human pancreatic cancer-derived cells with a recombinant SV40 vector carrying luciferase reporter gene. We measured transgene expression in unselected cells up to 3 weeks later. Despite continuous cellular proliferation in the interim, unselected transduced cells continued to express the transgene.
The mechanism by which SV40 persists into cellular DNA is unclear. Wild-type SV40 generally integrates infrequently; when it can complete a lytic cycle it does so. Alternatively, integration of recombinant SV40 genomes as been recently documented in diverse cell types. 63 The recombinant SV40s used in these studies carry only the late, structural genes of the virus. These genes are not transcribed in the absence of Tag. 64 SV40 DNA has been reported to associate with nuclear matrix. 65 This association may bring it into close apposition with cellular chromosomal DNA. A recent report notes that the SV40 origin of replication (ori) also associates with nuclear matrix. 66 Such an ori-nuclear matrix protein interaction may mediate a close approximation of recombinant SV40 genomes to cellular DNA which may be important in the ability of these rSV40 vectors to persist into cells. Further studies are needed to clarify this issue.
We next developed a recombinant SV40 viral vector to reintroduce into the pancreatic tumor cells a wild-type copy of the tumor-suppressor gene sst2. Our goal was to cause growth suppression, programmed cell death, and/or inhibit tumor angiogenesis in pancreatic tumors, in vitro and in vivo as we and others previously described. 32, 33, 59, 67 We choose this approach rather than complete genetic correction of the pancreatic genotype, because of the difficulty of achieving multiple gene restoration against a high background of mutation. Indeed, other important alterations in pancreatic cancer include mutations in the K-ras oncogene (90%), the p53 (85%) and Smad4 (50%) tumor-suppressor genes and the p16 (85% mutated and 15% silenced epigenetically) cell cycle inhibitor gene. [68] [69] [70] [71] Together, these alterations promote cellular proliferation, suppress inhibitory pathways, and facilitate tumor spread and metastasis.
Present cancer gene therapy approaches had limited success because such a therapeutic approach is prone to cause side effects as a result of the lack of tissue and cancer specificity. To target cancer cells without damaging normal cells, we have designed a SV40 vector in which sst2 expression was driven by the hTR promoter. Our results demonstrate that hTR promoter drives detectable transgene expression in the pancreatic cancer cell lines tested. Use of the hTR promoter in this experimental model highlights the potential utility of combining the hTR promoter with SV40 vectors, to achieve efficient gene expression in pancreatic cancer cells. As a result, we produced an SV40 vector in which hTR promoter controlled sst2 gene expression.
The effectiveness of this approach was demonstrated by using SV(hTR-sst2) in vitro to interrupt key pathways involved in continuing Capan-1 pancreatic tumor cell proliferation. Sst2 expression was readily detected by immunochemistry and Western blotting analysis following pancreatic cancer cells transduction by SV(hTR-sst2). As a consequence, Capan-1 cell proliferation was decreased, a direct consequence of induction of an autocrine loop with production of somatostatin by transduced cells, as we reported previously. 31, 33 When transferred in vivo into exponentially growing Capan-1 tumors implanted in athymic mice, SV40-mediated sst2 gene strongly inhibited tumor progression, compared to control SV40-transduced cells. Such inhibition was correlated with sst2 receptor expression in B60% of the tumor cells. In addition, detection of proliferating cell nuclear antigen Ki67 demonstrated a significant decrease in the number of cycling tumor cells. We have previously reported that in vivo gene transfer by PEI or adenoviral vectors in both orthotopic and ectopic models of pancreatic cancer scarcely transfected pancreatic cancer cells (5 and 15%, respectively), and waned rapidly. 32, 33 We demonstrated here that recombinant SV40 vectors transduced pancreatic cancer cells in vitro and in vivo with high efficacy, without selection, providing long-term gene expression. SV40-delivered sst2 gene transfer strongly impaired pancreatic cells proliferation and tumor progression. Taken together, these results represent the initial steps toward a novel approach to the gene therapy of pancreatic cancer using SV40 as a vector.
